Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin in HER2-expressing pancreatic cancer
NCT06233864Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, open-label trial of disitamab vedotin in pancreatic cancer (PC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 12 months. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06233864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233864.